The overall objective is to construct and optimize novel human CEA-based DNA vaccines for the effective immunotherapy of colon carcinoma. The investigators will test the hypothesis that peripheral T cell tolerance to these tumor self-antigens can be overcome by DNA vaccines boosted by effective adjuvants designed to generate cytolytic T lymphocyte (CTLs) specific for CEA epitopes expressed as MHC class I complexes on colon carcinoma cells. Emphasis will be on optimizing antigen processing and presentation in mouse models either transgenic for CEA or double transgenic for CEA and HLA-A2.1Kb.
Their aim i s to use such models for optimization of vaccine by antibody-cytokine fusion proteins and to investigate basic concepts such as mechanisms of T cell co-stimulation, generation of tumor-specific CTLs and T memory cells and establish principles for adoptive immunotherapy.
The specific aims designed to achieve these objectives are: 1) construction of optimal human CEA-specific DNA vaccines containing first the entire CEA gene and then minigenes encoding specific CEA peptides with HLA-A*0201 anchor residues. Delivery of the vaccines by injction of naked KNA or orally by galvage using attenuated strains of either Salmonella typhimurium or Listeria monocytogenes; 2) optimization of antigen processing in the 20S proteasome and presentation by using ubiquitinated versions of the entire CEA gene, minigenes encoding several CEA nonapeptides organized as as a string of beads or direct targeting of single CEA or repeat epitopes to the endoplasmic reticulum; 3) achievement of optimal adjuvanticity using either unmethylated CpG dinucleotide motifs or CD40 Ligand/Trimer co-expression; and 4) determination whether antibody-IL2 fusion proteins can effectively boost DNA vaccines to achieve optimal, long-lived tumor-protective immunity, as well as eradicate established metastases, and identification of immunological mechanisms involved in generating tumor-specific CTLs and T memory cells. The achievement of this proposal's objectives should lead to the design of effective DNA vaccines based on rational immunological principles that may ultimately lead to the improved treatment of colon cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
1R01CA083856-01A1
Application #
6196918
Study Section
Experimental Immunology Study Section (EI)
Program Officer
Yovandich, Jason L
Project Start
2000-05-08
Project End
2004-04-30
Budget Start
2000-05-08
Budget End
2001-04-30
Support Year
1
Fiscal Year
2000
Total Cost
$398,925
Indirect Cost
Name
Scripps Research Institute
Department
Type
DUNS #
City
La Jolla
State
CA
Country
United States
Zip Code
92037
Reisfeld, Ralph A (2013) The tumor microenvironment: a target for combination therapy of breast cancer. Crit Rev Oncog 18:115-33
Loeffler, Markus; Kruger, Jorg A; Niethammer, Andreas G et al. (2006) Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake. J Clin Invest 116:1955-62
Zhou, He; Luo, Yunping; Kaplan, Charles D et al. (2006) A DNA-based cancer vaccine enhances lymphocyte cross talk by engaging the NKG2D receptor. Blood 107:3251-7
Kim, Bumseok; Suvas, Susmit; Sarangi, Pranita P et al. (2006) Vascular endothelial growth factor receptor 2-based DNA immunization delays development of herpetic stromal keratitis by antiangiogenic effects. J Immunol 177:4122-31
Xiang, Rong; Mizutani, Noriko; Luo, Yunping et al. (2005) A DNA vaccine targeting survivin combines apoptosis with suppression of angiogenesis in lung tumor eradication. Cancer Res 65:553-61
Zhou, He; Luo, Yunping; Lo, Jeng-fan et al. (2005) DNA-based vaccines activate innate and adaptive antitumor immunity by engaging the NKG2D receptor. Proc Natl Acad Sci U S A 102:10846-51
Niethammer, Andreas G; Wodrich, Harald; Loeffler, Markus et al. (2005) Multidrug resistance-1 (MDR-1): a new target for T cell-based immunotherapy. FASEB J 19:158-9
Reisfeld, Ralph A; Niethammer, Andreas G; Luo, Yunping et al. (2004) DNA vaccines suppress tumor growth and metastases by the induction of anti-angiogenesis. Immunol Rev 199:181-90
Zhou, He; Luo, Yunping; Mizutani, Masato et al. (2004) A novel transgenic mouse model for immunological evaluation of carcinoembryonic antigen-based DNA minigene vaccines. J Clin Invest 113:1792-8
Luo, Yunping; O'Hagan, Derek; Zhou, He et al. (2003) Plasmid DNA encoding human carcinoembryonic antigen (CEA) adsorbed onto cationic microparticles induces protective immunity against colon cancer in CEA-transgenic mice. Vaccine 21:1938-47

Showing the most recent 10 out of 15 publications